Anacor extends agreement for neglected disease R&D
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has extended a licence and drug development agreement with the Drugs for Neglected Disease initiative (DNDi) to develop new therapies for sleeping sickness, visceral leishmaniasis and Chagas disease.